2026-04-23T16:02:02Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/51752024-10-31T12:01:45Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605
Repisalud
author
Mateos-Hernandez, Lourdes
author
Villar, Margarita
author
Doncel-Perez, Ernesto
author
Trevisan-Herraz, Marco
author
Garcia-Forcada, Angel
author
Romero Ganuza, Francisco
author
Vazquez, Jesus
author
de la Fuente, Jose
funder
European Commission
funder
University of Castilla-La Mancha (España)
2017-10-20T10:33:51Z
2017-10-20T10:33:51Z
2016
Oncotarget. 2016; 7(46):74582-74591
1949-2553
http://hdl.handle.net/20.500.12105/5175
27776345
10.18632/oncotarget.12789
Oncotarget
Guillain-Barre syndrome (GBS) is an autoimmune-mediated peripheral neuropathy of unknown cause. However, about a quarter of GBS patients have suffered a recent bacterial or viral infection, and axonal forms of the disease are especially common in these patients. Proteomics is a good methodological approach for the discovery of disease biomarkers. Until recently, most proteomics studies of GBS and other neurodegenerative diseases have focused on the analysis of the cerebrospinal fluid (CSF). However, serum represents an attractive alternative to CSF because it is easier to sample and has potential for biomarker discovery. The goal of this research was the identification of serum biomarkers associated with recovery from GBS. To address this objective, a quantitative proteomics approach was used to characterize differences in the serum proteome between a GBS patient and her healthy identical twin in order to lessen variations due to differences in genetic background, and with additional serum samples collected from unrelated GBS (N = 3) and Spinal Cord Injury (SCI) (N = 3) patients with similar medications. Proteomics results were then validated by ELISA using sera from additional GBS patients (N = 5) and healthy individuals (N = 3). All GBS and SCI patients were recovering from the acute phase of the disease. The results showed that Piccolo, a protein that is essential in the maintenance of active zone structure, constitutes a potential serological correlate of recovery from GBS. These results provided the first evidence for the Piccolo's putative role in GBS, suggesting a candidate target for developing a serological marker of disease recovery.
eng
Neuropathy
Proteomics
Biomarker
Guillain-Barre
Neurology
Immunology and Microbiology Section
Immune response
Immunity
IMMUNE-MEDIATED NEUROPATHIES
CEREBROSPINAL-FLUID
MULTIPLE-SCLEROSIS
PERIPHERAL NEUROPATHIES
PEPTIDE IDENTIFICATION
MOLECULAR MIMICRY
MASS-SPECTROMETRY
SYNDROME GBS
ANTIGANGLIOSIDE
CELLS
Quantitative proteomics reveals Piccolo as a candidate serological correlate of recovery from Guillain-Barre syndrome
journal article
URL
https://repisalud.isciii.es/bitstreams/d440f98d-b2fe-428b-95fc-c60137e19980/download
File
MD5
370093ade69b638fbf3a1701b1ac1b5f
1785119
application/pdf
QuantitativeProteomicsRevealsPiccolo_2016
URL
https://repisalud.isciii.es/bitstreams/e3f162f9-4d21-4e08-a958-8a1351d43a79/download
File
MD5
2629ba0d211c962f434687223795b3a9
131584
application/vnd.ms-excel
QuantitativeProteomicsRevealsPiccolo_2016_suppl
URL
https://repisalud.isciii.es/bitstreams/7fc1527d-11ad-403e-859d-2ce227baae51/download
File
MD5
5efa2a23c6230388dde821592babc818
41912
text/plain
QuantitativeProteomicsRevealsPiccolo_2016.txt
URL
https://repisalud.isciii.es/bitstreams/612b48ca-208a-4d73-9d14-671d2cd72adf/download
File
MD5
5efa2a23c6230388dde821592babc818
41912
text/plain
QuantitativeProteomicsRevealsPiccolo_2016.txt
URL
https://repisalud.isciii.es/bitstreams/57a0a23f-51a8-4529-aef7-8a676f6ec851/download
File
MD5
c88088378574ea5f8c3799ed93107886
57320
text/plain
QuantitativeProteomicsRevealsPiccolo_2016_suppl.txt